title: The benefit of using CT-perfusion imaging for reliable response monitoring in patients with gastrointestinal stromal tumor (GIST) undergoing treatment with novel targeted agents.
abstract: Solely size-based response criteria may be unreliable in patients with gastrointestinal stromal tumors (GIST) treated with tyrosine kinase inhibitors, because they typically underestimate responses to treatment. As GISTs are generally hypervascularized and novel targeted drugs knowingly affect angiogenic signaling pathways, perfusion measurements are expected to deliver important information about their efficacy. This pictorial essay illustrates the benefit of using complementary CT-perfusion-based measurements for more accurate evaluation of response to therapy in GIST.
authors.affiliation: Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Tübingen.
authors.forename: Martina
authors.initials: M
authors.lastname: Betz
authors.forename: Hans Georg
authors.initials: HG
authors.lastname: Kopp
authors.forename: Daniel
authors.initials: D
authors.lastname: Spira
authors.forename: Claus D
authors.initials: CD
authors.lastname: Claussen
authors.forename: Marius
authors.initials: M
authors.lastname: Horger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003287:Contrast Media; D005770:Gastrointestinal Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D046152:Gastrointestinal Stromal Tumors / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D021621:Imaging, Three-Dimensional; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011857:Radiographic Image Interpretation, Computer-Assisted; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: Volume perfusion CT (VPCT); gastrointestinal stromal tumor (GIST); multitargeted tyrosine kinase inhibitors (TKI); patterns of response